Pfizer’s $43 Billion Seagen Takeover Faces FTC Scrutiny
- Expected development could signal antitrust difficulties
- Agency request likely to lengthen deal’s review by months
Seagen headquarters in Bothell, Washington.
Photographer: David Ryder/BloombergThis article is for subscribers only.
Pfizer Inc.’s proposed $43 billion takeover of Seagen Inc. will undergo an in-depth antitrust review by the Federal Trade Commission.
Seagen disclosed in a regulatory filing that both companies received a so-called second request seeking additional information on the deal from the antitrust agency. In June, the companies withdrew their filing and submitted it again to give the FTC more time to conduct their initial review.